Boyu Capital
PE-backed Waterdrop falls on debut after $360m US IPO
Waterdrop, a China-based insurance, medical crowdfunding and mutual aid platform, fell 19% on its New York Stock Exchange debut following a $360 million IPO.
PE-backed Brii Bioscience pursues Hong Kong listing
Brii Biosciences, a three-year-old Chinese biotech start-up that has raised approximately $415 million in private funding from the likes of Sequoia Capital China, Boyu Capital, and Yunfeng Capital, has filed for a Hong Kong IPO.
China's Kuaishou surges on debut after $5.4b Hong Kong IPO
Kuaishou, a Chinese video-sharing and social networking platform backed by Tencent Holdings, 5Y Capital and DST Global, started trading at nearly three times its IPO price following a Hong Kong IPO that valued the company at HK$1.1 trillion ($142 billion).
Aspex leads $200m Series E for Hong Kong's Klook
Aspex Management has led a $200 million Series E round for Klook as the Hong Kong travel app pivots to domestic holiday services during a freeze in international tourism.
AVCJ Awards 2020: Deal of the Year - Mid Cap: Perfect Diary
Perfect Diary’s $100 million Series D round came after the Chinese company proved itself with multiple hit color cosmetics brands and eight months ahead of a bumper US listing
China AI specialist 4Paradigm receives $700m Series D
Boyu Capital, Primavera Capital Group, and Hopu Investments have led a $700 million Series D round for 4Paradigm, a Chinese artificial intelligence (AI) technology developer that serves enterprise customers.
LAV, Arch lead $100m round for China's SciNeuro
SciNeuro Pharmaceuticals, a China and US-based drug developer specializing in treatments for central nervous system (CNS) disorders, has announced its formal launch with a $100 million funding round.
PE-backed Antengene trades flat after $359m HK IPO
Antengene, a China-based drug developer that previously raised $238 million across three private funding rounds, closed roughly flat on its first day of trading in Hong Kong following a HK$2.78 billion ($359 million) IPO.
PE-backed Perfect Diary jumps 75% on debut after $616m IPO
Yatsen Holding, the parent company of Chinese cosmetics brand Perfect Diary, gained 75% on its first day of trading on the New York Stock Exchange following a $616.9 million IPO.
Sequoia, Matrix back $200m Series A for China’s D3 Bio
D3 Bio, a Chinese drug developer that studies and specifically targets areas where existing approaches to care are not delivering satisfactory outcomes, has raised $200 million in Series A funding.
Hillhouse, Boyu, CareCapital back condom maker
Chinese private equity firms Hillhouse Capital, Boyu Capital and CareCapital Partners, a specialist dental and consumer health investor, have paid $200 million for a 40% stake in condom brand LifeStyles.
China short video platform Kuaishou files for Hong Kong IPO
Kuaishou, a Chinese video sharing and social networking platform backed by the likes of Tencent Holdings, Sequoia Capital China, Boyu Capital and DST Global, has filed for a Hong Kong IPO.
China cosmetics brand Perfect Diary files for US IPO
Yatsen Holding, the parent company of Chinese cosmetics brand Perfect Diary has filed for a US IPO, potentially delivering a liquidity event for the likes of Hillhouse Capital, ZhenFund and Gaorong Capital.
China's Yuanfudao hits record valuation with $2.2b round
Yuanfudao, a Chinese education start-up that targets the K-12 segment, has raised $2.2 billion in Series G funding at a valuation of $15.5 billion, nearly double the valuation of its previous round, which closed in April.
China biotech player Antengene raises $97m Series C
Fidelity Investments has led a $97 million Series C round for Chinese hematology and oncology biotech developer Antengene.
Ocumension climbs on debut after $184m Hong Kong IPO
Ocumension Therapeutics, a Chinese drug developer targeting eye diseases that counts Boyu Capital and Temasek Holdings among its backers, posted a 152% gain on debut following a HK$1.5 billion ($200 million) Hong Kong IPO.
PE-backed Hygeia completes $286m Hong Kong IPO
Chinese radiotherapy business Hygeia Healthcare, which counts Warburg Pincus, Boyu Capital, and CITIC Capital among its investors, raised HK$2.22 billion ($286.4 million) in its Hong Kong IPO.
Hillhouse leads $1b round for China’s Yuanfudao
Chinese online education start-up Yuanfudao has seen its valuation soar to $7.8 billion on closing a $1 billion funding round led by Hillhouse Capital.
Boyu leads $300m round for Chinese apartment rental player
Boyu Capital has led a $300 million Series A round of funding in Cjia.com, a serviced apartment brand created by Huazhu Hotels Group and IDG Capital.
Alibaba, Yunfeng invest $700m in NetEase Cloud Music
NetEase Cloud Music, one of China's largest music streaming platforms, has secured a $700 million investment from Alibaba Group and Yunfeng Capital, a private equity firm established by Alibaba founder Jack Ma.
Boyu co-founder Mary Ma dies at 66
Mary Ma, the long-serving Lenovo Group executive who forged a second career in private equity with TPG Capital and Boyu Capital, has died aged 66.
PE-backed Hansoh Pharma completes $1b Hong Kong IPO
Hansoh Pharmaceutical Group, a Chinese drug developer that counts Hillhouse Capital and Boyu Capital among its investors, has raised HK$7.86 billion ($1 billion) through a Hong Kong IPO.
Boyu leads round for Chinese health insurance platform
Waterdrop, a Chinese online health insurance platform that runs mutual aid programs and provides brokerage services, has raised RMB1 billion ($145 million) in Series C funding led by Boyu Capital.
Deal focus: Antengene targets unmet cancer problems
Chinese drug developer Antengene wins backing from the likes of Boyu Capital and FountainVest Partners for a pipeline of treatments that address the country's growing cancer problem